Lisata Therapeutics (LSTA) Institutional Ownership $2.56 +0.10 (+4.07%) As of 06/12/2025 03:16 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Lisata Therapeutics (NASDAQ:LSTA)CurrentInstitutional OwnershipPercentage8.94%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$112.42KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$159.37K Get LSTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lisata Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LSTA Institutional Buying and Selling by Quarter Lisata Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/7/2025 BML Capital Management LLC216,853$510K0.4%-23.8%2.517% 2/17/2025 Citadel Advisors LLC23,273$69K0.0%N/A0.277% 2/14/2025 Dimensional Fund Advisors LP25,226$75K0.0%+45.5%0.301% 8/9/2024 Dimensional Fund Advisors LP17,336$60K0.0%+48.2%0.209% 4/23/2024 BML Capital Management LLC284,669$888K0.6%+5.5%3.426% 1/30/2024 BML Capital Management LLC269,839$737K0.6%+10.7%3.315% 2/13/2023 BML Capital Management LLC243,839$617K0.6%N/A3.102% (Data available from 1/1/2016 forward) LSTA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LSTA shares? During the previous two years, the following institutional investors and hedge funds held shares of Lisata Therapeutics shares: BML Capital Management LLC ($510K), and Dimensional Fund Advisors LP ($75K), Citadel Advisors LLC ($69K).Learn more on LSTA's institutional investors. What percentage of Lisata Therapeutics stock is owned by institutional investors? 8.94% of Lisata Therapeutics stock is owned by institutional investors. Learn more on LSTA's institutional investor holdings. Which institutional investors have been buying Lisata Therapeutics stock? The following institutional investors have purchased Lisata Therapeutics stock in the last 24 months: BML Capital Management LLC ($40.83K), Citadel Advisors LLC ($23.27K), and Dimensional Fund Advisors LP ($13.53K). How much institutional buying is happening at Lisata Therapeutics? Institutional investors have bought a total of 77,628 shares in the last 24 months. This purchase volume represents approximately $229.67K in transactions. Which Lisata Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Lisata Therapeutics stock in the last 24 months: BML Capital Management LLC ($67.82K). How much institutional selling is happening at Lisata Therapeutics? Institutional investors have sold a total of 67,816 shares in the last 24 months. This volume of shares sold represents approximately $159.37K in transactions. Related Companies Vaxart Institutional Ownership Climb Bio Institutional Ownership Jasper Therapeutics Institutional Ownership Adagene Institutional Ownership XBiotech Institutional Ownership BeyondSpring Institutional Ownership Citius Oncology Institutional Ownership Zura Bio Institutional Ownership OncoCyte Institutional Ownership Invizyne Technologies Institutional Ownership This page (NASDAQ:LSTA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.